Sector
PharmaceuticalsOpen
₹218.3Prev. Close
₹219.32Turnover(Lac.)
₹3,655.49Day's High
₹228.9Day's Low
₹215.852 Week's High
₹358.752 Week's Low
₹130Book Value
₹30.31Face Value
₹1Mkt Cap (₹ Cr.)
10,150.87P/E
54.16EPS
4.05Divi. Yield
0.27Relonchem Ltd has secured Marketing Authorisation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for Baclofen 10 mg Tablets
The US Food and Drug Administration (FDA) approved the pharmaceutical company's Abbreviated New Drug Application (ANDA) for Loratadine Tablets USP 10 mg.
Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 45.32 | 45.32 | 134.03 | 40.93 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 1,177.39 | 1,066.01 | 650.64 | 558.79 |
Net Worth | 1,222.71 | 1,111.33 | 784.67 | 599.72 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Revenue | 599.54 | 433.41 | 294.66 | 215.83 |
yoy growth (%) | 38.33 | 47.08 | 36.51 | -39.73 |
Raw materials | -337.91 | -243.03 | -169.34 | -112.37 |
As % of sales | 56.36 | 56.07 | 57.47 | 52.06 |
Employee costs | -54.63 | -48.5 | -45.85 | -39.77 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Profit before tax | 124.32 | 52.72 | 16.65 | 11.94 |
Depreciation | -15.19 | -11.64 | -12.25 | -15 |
Tax paid | -25.94 | -14.82 | -4.22 | -0.4 |
Working capital | 82.13 | -10.16 | 7.89 | 46.78 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 38.33 | 47.08 | 36.51 | -39.73 |
Op profit growth | 59.06 | 96.13 | 48.84 | -76.42 |
EBIT growth | 116.05 | 146.78 | 47.96 | -83.19 |
Net profit growth | 159.55 | 205 | 7.64 | -83.84 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 2,177.41 | 1,852.14 | 1,490.84 | 1,376.18 | 1,134.21 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 2,177.41 | 1,852.14 | 1,490.84 | 1,376.18 | 1,134.21 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 50.42 | 59.31 | 41.85 | 6.69 | 0.33 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,805.5 | 137.46 | 4,33,031.98 | 1,181.05 | 0.75 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 6,108 | 78.27 | 1,62,251.74 | 594 | 0.49 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,541.5 | 26.74 | 1,24,457.39 | 1,438.15 | 0.84 | 4,134.87 | 360.72 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,322.7 | 61.63 | 1,12,419.76 | 485 | 0.84 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,556.9 | 54.56 | 1,05,504.58 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Mark Saldanha
Company Sec. & Compli. Officer
Harshavardhan Panigrahi
Non-Exec. & Independent Dir.
Seetharama Raju Buddharaju
Whole-time Director
Sandra Saldanha
Non-Exec. & Independent Dir.
Digant Mahesh Parikh
Whole-time Director
Varddhman Vikramaditya Jain
Non-Exec. & Independent Dir.
Abhinna Sundar Mohanty
Non Executive Director
Sunny Sharma
Independent Director
Shailaja Vardhan
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Marksans Pharma Ltd
Summary
Marksans Pharma Limited was formerly incorporated as Tasc Pharmaceuticals Limited in April, 1982. Pursuant to the Scheme of Amalgamation, name of the Company was changed from Tasc Pharmaceuticals Limited to Marksans Pharma Limited with effect from 10th October, 2005. The Company primarily engaged in the business of research, manufacture, marketing and sale of pharmaceutical formulation. The Companys research and development facilities are located in Verna, Goa and R & D center in Navi Mumbai.In 2004-05, the Company amalgamated with M/s. Marksans Pharma Limited (formerly M/s. Glenmark Laboratories Limited) pursuant to High Court order dated 19th August, 2005. As provided in the approved Scheme of Amalgamation, necessary shares were issued to the shareholders of the M/s. Marksans Pharma Limited (formerly M/s. Glenmark Laboratories Limited). The Company acquired majority stake in Nova Pharmaceuticals Australasia Private Limited in 2005; further, it acquired two companies, Bell Sons & Company (Druggists) Limited and Relonchem Limited in the UK in 2008. The Company received first ANDA approval in the USA in 2011. It acquired Time-Cap Laboratories Inc. in the US in 2015. The Company launched the CNS-Cerebella division in FY 2017-18. It launched soft gelatin capsules, a niche category, Launched two products and received CRL for 4 ANDAs for approval with the USFDA. The Company commissioned a new R&D center at Navi Mumbai, apart from one in Goa in 2019-20. The Company acquired the bus
Read More
The Marksans Pharma Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹224 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Marksans Pharma Ltd is ₹10150.87 Cr. as of 30 Apr ‘25
The PE and PB ratios of Marksans Pharma Ltd is 54.16 and 7.70 as of 30 Apr ‘25
The 52-week high/low is the highest and lowest price at which a Marksans Pharma Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Marksans Pharma Ltd is ₹130 and ₹358.7 as of 30 Apr ‘25
Marksans Pharma Ltd's CAGR for 5 Years at 60.57%, 3 Years at 59.75%, 1 Year at 29.66%, 6 Month at -19.65%, 3 Month at -7.23% and 1 Month at -1.19%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.